May 2, 2009

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

.   .   

This meta-analysis of 53 previous randomized-controlled trials was done to compare erythopoietic agents plus red blood cell transfusions to transfusions alone in the management of anemia in patients with cancer. This study showed that treatment with erythropoiesis-stimulating agents resulted in increased mortality in patients with cancer.

Related Articles:

Anemia, Internal Medicine for Nephrologists

Comments are closed.